2229859-11-2

2229859-11-2 structure

Name: Mirzotamab
Chemical Name: Mirzotamab
CAS Number: 2229859-11-2
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-06-10 11:14:42
Modify Date: 2025-08-24 22:05:18
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclaxum (HY-137774), an BCL2L1 inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane therapy in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[1].

Name	Mirzotamab

Description	Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclaxum (HY-137774), an BCL2L1 inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane therapy in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC)[1].
Related Catalog	Research Areas >> Cancer
Target	CD276/B7-H3[1]
References	[1]. Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.

No Any Chemical & Physical Properties